CN212592565U - Support device for preventing I-shaped internal leakage - Google Patents

Abstract

The utility model belongs to the field of medical equipment, the utility model provides a leak support device in preventing I type, leak support and magnetic drive ware in preventing, leak the support in preventing include with the netted supporting layer of human arterial blood vessel shape phase-match metal, cover the tectorial membrane layer on the netted supporting layer of metal, and distribute in the nearly heart end in the tectorial membrane layer outside or distribute in the elasticity net layer of the nearly heart end in the tectorial membrane layer outside and telecentric simultaneously, the elasticity net layer is embedded to have magnetic particles, magnetic particles changes the magnetic field energy in the magnetic field that magnetic drive ware produced into heat energy, thereby make elasticity net layer take place deformation along with the change of temperature and fill in the gap that artery blood vessel's inner wall and tectorial membrane layer formed, thereby seal the tumor chamber completely, make the tumor chamber get into stable state. The device is simple to operate, and the diseased region in the DSA image can be released, so that the operation time can not be prolonged, and unnecessary risks are not brought. In addition, the magnetic driver has low manufacturing cost and can save medical resources.

Description

Support device for preventing I-shaped internal leakage

Technical Field

The utility model belongs to the field of medical equipment, concretely relates to prevent support device that leaks in I type.

Background

Aneurysms are among the most common vascular diseases that cause disability and death. It can be seen in any artery of the whole body, as is common in the elderly. Aneurysms can be of a variety of sizes, morphologies, and distributions, and the Ad Hoc Commission on Reporting Standards for Vascular Surgery Commission defines aneurysms as permanent, localized dilations of arterial vessel diameter 50% greater than normal arterial vessel diameter, for classification and standardization by clinical decision.

The earliest record of attempts to treat aneurysms originated in the 3 rd century, but until 1888 Matas et al completed the first true repair of aneurysms, i.e., the ligation of a branch artery within the lumen of the brachial aneurysm. In 1951, Dubost et al completed the first aneurysm suture repair procedure, which removed an abdominal aortic aneurysm from a patient and transplanted a 20 year old donor of thoracic aorta as an allograft into an abdominal aortic aneurysm patient, which survived 8 years after surgery. Open surgery to repair aneurysms is gradually perfected and optimized over the next 40 years, but its perioperative mortality rate is still as high as 5%. In 1991, Parodi et al first reported the experience of using an artificial endovascular stent complex to repair aortic aneurysms. After Food and Drug Administration (FDA) approval for clinical use of endovascular grafts, aneurysms, including peripheral aneurysms and aortic aneurysms, have undergone an evolution from open bypass repair to endovascular repair.

Compared with the traditional open operation, the covered stent for treating diseases such as aneurysm, arterial dissection and the like by using the endoluminal isolation operation has the advantages of small operation wound, quick postoperative recovery, short hospitalization time and the like, but the specific complication, i.e. internal leakage, cannot be completely avoided at present. Endoleaks are one of the most important complications after endoluminal exclusion, with incidence rates as high as 45%. The inner leakage can be classified into I-V type according to the generation mechanism. Wherein, the I-type internal leakage refers to that blood flows through the near-heart end or the far-heart end of the covered stent and leaks into the aneurysm cavity because the covered stent is poorly attached to the inner wall of the artery in the anchoring area; the incidence is about 10%, which is often found by intraoperative imaging. Immediate intraoperative treatment is required because the presence of type I endoleaks can result in high pressure within the aneurysm cavity, continued enlargement of the aneurysm and even risk rupture. It is believed that the incidence of type I endoleaks will be significantly increased with proximal anchoring zone < 10mm, and/or neck angulation > 60. Currently, the general treatment for the type I endoleaks found intraoperatively is: balloon dilatation, the addition of short length stent grafts, bare stents or embolization techniques using cyanoacrylate, Onyx glue, coil, fibrin glue. These techniques can handle most type I endoleaks; however, in some cases it may be difficult to achieve, for example, too short a proximal anchoring zone of an abdominal aortic aneurysm, and the application of a short graft segment at the proximal end may affect the renal artery blood supply.

Maldonado et al summarize the current effect of the above method on treating type I endoleaks: cyanoacrylate embolization success rate was 92.3%, proximal short-segment graft 80%, and coil 75%. The occurrence of type II endoleaks is not related to stent grafts and will not be described in detail. Type III endoleaks are the leakage of blood in the vascular cavity into the aneurysm cavity through the defect in the stent wall. The type IV internal leakage is another form of type III internal leakage and is characterized in that the blood in a blood vessel cavity is subjected to diffuse leakage from the covered stent within one month after the covered stent is implanted. The V-shaped endoleak is also called as 'internal tension' endoleak and refers to the condition that no obvious endoleak exists after the intracavity isolation operation through angiography or CT arterial imaging, the pressure in the aneurysm is increased, and the tumor cavity is enlarged. When the internal leakage occurs, no matter which treatment mode is adopted, the problem of success rate exists, and the problems of greatly increasing operation time and medical expense also exist; the prolonged operation time increases the risks in the operation and the incidence rate of postoperative infection of patients, and the high medical cost brings high economic burden to the patients and occupies more social resources.

SUMMERY OF THE UTILITY MODEL

The utility model relates to a solve above-mentioned problem and go on, aim at provides a leak support device in preventing I type.

The utility model provides a prevent leaking support device in I type for leak in the sealed I type has such characteristic, include: prevent interior hourglass support and magnetic drive, wherein, prevent interior hourglass support and include: the metal mesh supporting layer is matched with the shape of an arterial blood vessel of a human body; the film coating layer is covered on the metal reticular supporting layer; the elastic grid layer is distributed at the proximal end outside the film coating layer or at the proximal end and the distal end outside the film coating layer; and the magnetic particles are embedded in the elastic grid layer, the magnetic driver is used for generating a magnetic field at the position of the inner leakage prevention support, and the magnetic particles convert the magnetic field energy of the magnetic field into heat energy so that the elastic grid layer deforms along with the change of temperature and is filled in a gap formed by the inner wall of the arterial blood vessel and the film coating layer.

The utility model provides an in preventing I type internal leakage support device, can also have such characteristic: the magnetic particles are manganese-zinc ferrite or ferroferric oxide, and the volume ratio of the magnetic particles to the elastic grid layer is 45: 100-75: 100.

The utility model provides an in preventing I type internal leakage support device, can also have such characteristic: wherein, the material of the elastic grid layer is poly L-lactic acid.

The utility model provides an in preventing I type internal leakage support device, can also have such characteristic: wherein, the elastic grid layer does not exceed the edges of the ends of the metal net-shaped supporting layer and the coating layer.

The utility model provides an in preventing I type internal leakage support device, can also have such characteristic: wherein, the thickness of the elastic grid layer is 1 mm-5 mm.

The utility model provides an in preventing I type internal leakage support device, can also have such characteristic: the elastic grid layer is provided with grooves which are triangular grooves, the elastic grid layer is formed by combining edges of a plurality of polyhedrons into triangular grids which are uniformly arranged, and the triangular grids are provided with triangular grooves.

The utility model provides an in preventing I type internal leakage support device, can also have such characteristic: the polyhedron is a double triangular pyramid, and the long axis direction of the double triangular pyramid is perpendicular to the long axis direction of the internal leakage prevention support.

The utility model provides an in preventing I type internal leakage support device, can also have such characteristic: wherein, a plurality of two triangular pyramid posts are connected side by side and are formed the individual layer, crisscross multilayer staggered structure that forms in the junction of two triangular pyramid posts between a plurality of individual layers, and multilayer structure forms the cylindrical outside of enclosing at the tectorial membrane layer.

The utility model provides an in preventing I type internal leakage support device, can also have such characteristic: wherein the magnetic driver generates a magnetic field having a strength of 1kA/m to 50 kA/m.

The utility model provides an in preventing I type internal leakage support device, can also have such characteristic: the magnetic driver comprises a vertically arranged driving arm and two driving plates which are arranged on the driving arm in an up-and-down parallel mode, a plurality of excitation groups are arranged in the driving plates, and the excitation groups generate a magnetic field when being electrified.

Action and effect of the utility model

According to the utility model provides a prevent leaking support device in I type, the metal supporting layer has supported the blood vessel, elasticity net check layer covers on the tectorial membrane layer, the magnetic field that the magnetic particle magnetic drive ware that distributes in elasticity net check layer produced generates heat down, elasticity net check layer expands under the heat effect, fill up the gap between tectorial membrane layer and the blood vessel inner wall, and because blood enters into elasticity net check layer, the velocity of flow reduces, when the blood vessel has the hard piece of artery, the hard piece of artery is held in the recess, consequently, elasticity net check layer and tectorial membrane layer make the leak no longer bleed together, overcome the tectorial membrane layer and not have the recess, can't hold the hard piece of artery, thereby leave the defect that the space made the unable healing of leak. Elastic grid layer fills up the space for blood flow can not directly rush into the tumor chamber, and blood can not be recharged in the tumor chamber, and the tumor chamber can get into stable state after the blood that persists in the tumor chamber solidifies, and then endothelial cell hyperplasia grows into the tumor chamber, makes the difficult emergence of tumor chamber break. When a new arteriosclerosis plaque is newly generated on the vessel wall and the tectorial membrane layer is jacked up to generate a new gap, the stent can be conveniently placed in the magnetic field again to expand the elastic grid layer, and then the gap is propped up by the arteriosclerosis plaque to be filled, so that the tumor cavity is completely sealed, and the tumor cavity is in a stable state. Therefore, a new stent does not need to be implanted again, so that the pain and the operation risk of a patient are reduced, and the medical resources are saved.

The elastic mesh layer has two functions, namely physical barrier, so that the flow speed of blood at the position is greatly reduced, and coagulation is promoted; meanwhile, the grid structure also serves as a matrix formed by fibrosis, and is beneficial to the growth of fibroblasts, so that the tumor cavity is further stabilized.

The device is simple to operate, and the diseased region in the DSA image can be released, so that the operation time can not be prolonged, and unnecessary risks are not brought. In addition, the magnetic driver has low manufacturing cost and can save medical resources.

Drawings

Fig. 1 is a schematic view of the overall structure of an inner leakage prevention bracket according to embodiment 1 of the present invention;

fig. 2 is a schematic view of the internal structure of an internal leakage prevention bracket according to embodiment 1 of the present invention;

fig. 3 is a schematic view of the surface structure of the elastic mesh layer in embodiment 1 of the present invention;

fig. 4 is a schematic diagram of the distribution structure of the magnetic particles in the elastic mesh layer according to embodiment 1 of the present invention;

fig. 5 is a schematic structural view of a magnetic actuator according to embodiment 1 of the present invention;

fig. 6 is a schematic structural view of basic units of an elastic mesh layer in embodiment 1 of the present invention;

fig. 7 is a partial sectional view of the elastic mesh layer in the long axis direction of the inner leakage prevention stent according to embodiment 1 of the present invention;

fig. 8 is a schematic view of the staggered arrangement of the single layers of the elastic mesh layer in example 1 of the present invention; and

fig. 9 is a schematic view of the entire structure of the inner leakage prevention bracket according to embodiment 2 of the present invention.

Detailed Description

In order to make the utility model realize that the technical means, creation characteristics, achievement purpose and efficiency are easy to understand and understand, it is right to combine embodiment and drawing below the utility model discloses prevent leaking support device in I type and make concrete explanation.

Because cause the reason that leaks in the I type many, cause the blood stream to leak the reason in aneurysm intracavity many near heart end or far heart end of covered stent, the utility model discloses a leak in the I type that the support caused to various reasons in preventing all has the effect of prevention. The embodiment will be described by taking only an example of poor adhesion between the stent graft and the inner wall of the artery in the anchor region due to an arteriosclerotic plaque.

The following describes embodiments of the present invention with reference to the drawings.

< example 1>

The embodiment specifically describes the bracket device for preventing the I-shaped inner leakage.

Fig. 1 is a schematic view of the overall structure of an internal leakage prevention stent according to embodiment 1 of the present invention, in which directions a and a are both in the direction of arterial blood flow, one end close to the directions a is a proximal end, and the other end away from the directions a is a distal end; fig. 2 is a schematic view of the internal structure of an internal leakage prevention bracket according to embodiment 1 of the present invention; fig. 3 is a schematic view of the surface structure of the elastic mesh layer in embodiment 1 of the present invention; fig. 4 is a schematic diagram of the distribution structure of the magnetic particles in the elastic mesh layer according to embodiment 1 of the present invention; fig. 5 is a schematic structural view of a magnetic actuator according to embodiment 1 of the present invention.

As shown in fig. 1 to 5, the I-shaped inner leakage prevention bracket device includes an inner leakage prevention bracket 10 (hereinafter referred to as an inner leakage prevention bracket) and a magnetic driver.

The innerleakage prevention support 10 has a metalmesh support layer 11, acoating layer 12, and anelastic mesh layer 13.

The metalmesh support layer 11 is positioned at the innermost layer and has a shape matched with the shape of the arterial blood vessel. The metalmesh supporting layer 11 has diamond-shaped meshes, and can be compressed and expanded in the circumferential direction to an original shape under the action of external force.

Thecoating layer 12 covers the outer surface of the metallicmesh support layer 11. Theelastic mesh layer 13 is located on the outer layer of thefilm coating layer 12 at the proximal end. On the side facing the blood flow (i.e. the direction a shown in fig. 1), i.e. the proximal end, the impact force of the blood flow is strong and directed towards the slit where the arteriosclerotic plaque is supported, and the blood flow is particularly liable to rush into the slit in this direction, while on the distal end, the blood flow is difficult to rush into the slit because the opening of the slit is along the direction of the blood flow, and even if there is a slit, the blood flow therein is slow, and after a while, the blood therein is naturally coagulated and the risk is very small. Therefore, the elastic mesh layer is not required to be arranged at the far end of the internalleakage prevention support 10, so that the manufacturing cost can be reduced.

Theelastic mesh layer 13 has a thickness of 1mm to 5mm, and is adhered to thecoating layer 12 so as not to exceed the edges of the ends of the metalmesh support layer 11 and thecoating layer 12, and preferably to be slightly retracted inward with respect to the ends of the metalmesh support layer 11.

Theelastic mesh layer 13 has triangular meshes arranged uniformly and having triangular grooves for receiving the arterial hard mass.

Magnetic particles 14 are uniformly distributed in theelastic mesh layer 13. Themagnetic particles 14 can convert magnetic field energy of a magnetic field into heat energy, and the volume ratio of the heat energy to theelastic grid layer 13 is 45: 100-75: 100. In the present embodiment, themagnetic particles 14 are manganese zinc ferrite. The Mn-Zn ferrite is one of soft magnetic ferrites, has good biocompatibility and higher initial permeability.

The heat generated by the Mn-Zn ferrite heats theelastic mesh layer 13, so that the elastic mesh layer deforms along with the change of temperature and is filled in a gap formed by the inner wall of the artery blood vessel and the coating layer.

A commonly used material for thecoating layer 12 is polyester, also known as ethylene terephthalate.

Theelastic mesh layer 13 is made of poly-L-lactic acid, which is a medical polymer material with good biocompatibility and biological absorbability, has shape memory property, has a shape memory function below 100 ℃, and has a deformation recovery temperature lower than 100 ℃. And when the temperature is higher than the deformation temperature, the material begins to expand by heating and is restored to the original size before compression.

Mixing manganese-zinc-iron powder and poly-L-lactic acid according to a volume ratio of 45: 100-75: 100, adding the mixture into a hopper of a 3D printing consumable wire drawing machine, setting the temperature at 180 ℃, waiting for 10-30 s to stabilize the temperature, starting a 3D printing motor, adjusting a fulcrum, maintaining smooth wire discharge of an extruder, adjusting the wire discharge speed, and adjusting and measuring the diameter of a wire. Wherein the poly-L-lactic acid is melted at 180 ℃, so that the manganese-zinc ferrite is uniformly dispersed in the poly-L-lactic acid. Then modeling is carried out on theelastic grid layer 13 through 3Dmax software, then the grid layer three-dimensional model is led into a 3D printer for printing and shaping, the printing melting temperature is 180 ℃, the diameter of a spray head is 0.1mm, the printing speed is 30mm/s, and theelastic grid layer 13 with themagnetic particles 14 uniformly distributed is obtained through printing.

In this embodiment, theelastic mesh layer 13 is compressed at a high temperature (180 ℃ to 210 ℃) and then wrapped outside thecoating layer 12, and is stored at a low temperature (25 ℃ to 37 ℃) to obtain the inner leakage prevention stent 1 with the shape memory characteristic. The metal mesh-like support layer 11 is also in a compressed state at this time, that is, the innerleakage prevention stent 10 is in a compressed state entirely outside the body. When in use, the stent is guided into the tumor cavity of the human body, and is heated to the safe temperature of the human body below 48 ℃ under the action of an external magnetic field, and the grid layer generates heat to deform and expand to the original shape, thereby playing the role of plugging. The whole size of the stent can be adjusted by a balloon or a stent release system, and the size of the released stent is adjusted according to the size of a tumor cavity during release of the contrast.

As shown in fig. 5, the magnetic actuator includes a vertically arrangedactuator arm 21 and twoactuator plates 22 mounted on theactuator arm 21 in parallel up and down.

Thedrive plate 22 incorporates therein a plurality of field groups as magnetic field generating sources, each field group being wound with a superconducting coil and generating a magnetic field when energized. The size of the driving magnetic field can be controlled by controlling the size of the electrified current, and the working time of the magnetic field can be controlled by controlling the time of the electrified current.

Each field group can generate a magnetic field with controllable magnitude and polarity, and the magnetic field intensity of the drivingplate 22 can reach 1kA/m-50 kA/m. Medical staff can move the magnetic driver to the position of the support in the human body and electrify the magnetic driver, the excitation group generates an external driving magnetic field with specific size, and the magnetic material of theelastic grid layer 13 converts the magnetic field energy of the external magnetic field into heat energy to deform theelastic grid layer 13.

The volume ratio of the Mn-Zn ferrite powder to the poly-L-lactic acid in this example was 60: 100. In vitro experimental results show that when the temperature control material is placed under a magnetic field with the strength of 30kA/m for 5s, the temperature control material expands to the initial size by the heat generated by the manganese-zinc ferrite. The heat generated by the manganese zinc ferrite can cause theelastic mesh layer 13 to heat up to 37 deg.c.

Fig. 6 is a schematic structural view of basic units of the elastic mesh layer in embodiment 1 of the present invention.

As shown in fig. 6, the basicconstituent unit 131 of theelastic mesh layer 13 is formed of the prism of a double triangular pyramid, and both the inside and the cylindrical surface are hollow.

Fig. 7 is a partial sectional view of the elastic mesh layer in the long axis direction of the inner leakage prevention stent according to example 1 of the present invention.

As shown in fig. 7, the long axis of thebasic unit 131 is perpendicular to the central axis of the stent, and a plurality ofbasic units 131 are connected side by side to form a single layer.

Fig. 8 is a schematic view of the staggered arrangement of the single layers of the elastic mesh layer in example 1 of the present invention.

As shown in fig. 8, the plurality of single layers are staggered at the junction of two basicconstituent units 131 to form a multi-layered staggered structure. The multi-layer structure forms a cylindrical shape and surrounds the elastic temperature-controllable grid layer 13 which is provided with uniformly arranged triangular grids and formed at the proximal end of the I-shaped inner leakage prevention support device. The triangular mesh has triangular grooves.

Theelastic mesh layer 13 has a fixed shape and volume at a lower temperature before insertion into the body. After preventinginterior hourglass support 10 is released, when putting into the blood vessel that the aneurysm takes place the department in, under the effect of external magnetic field, the magnetic particle manganese zinc ferrite in theelasticity net layer 13 produces the heat, the poly L-lactic acid in theelasticity net layer 13 is heated the inflation, fill betweentectorial membrane layer 12 and vascular wall, make the blood flow can not directly rush into the tumor chamber, blood coagulation can take place after a period in the blood in elasticitynet layer 13 space, thereby seal the tumor chamber completely, make the tumor chamber get into stable state, and the hard piece of artery just is held by the triangle-shaped recess.

In the case of gaps, there is an adverse effect that endothelial cells in the inner wall of the blood vessel cannot grow into the inside of the stent because the gaps are always under the impact of blood flow, so that the edges of the stent cannot be covered by the endothelial cells and are connected with the endothelium of the blood vessel. After the internal leakage prevention stent is implanted, because the blood flow speed at the gap is reduced, epithelial cells on the blood vessel wall near the gap of the internal leakage prevention stent have sufficient time to gradually grow into the inner surface of the metal supporting layer of the internal leakage prevention stent, and finally, the inner surface of the internal leakage prevention stent is completely covered and is connected with the vascular endothelium at two ends into a whole. Thereby make and prevent interior hourglass support entering stable state, the tumour intracavity can not be recharged blood, and the tumour chamber can enter stable state after the blood that persists in the tumour chamber solidifies, and then endothelial cell hyperplasia grows into the tumour chamber for the difficult emergence of tumour chamber is ruptured. The length of theelastic mesh layer 13 does not exceed the edges of the upper and lower ends of the metalmesh support layer 11 and thecoating layer 12. The reason for this is to prevent theelastic mesh layer 13 from protruding from the edge of the I-shapedendoleak stent 10, causing blood flow therein to coagulate, forming thrombus, and embolizing the blood vessel under the impact of the blood flow into the blood vessel.

The method of implanting the type I endoleak prevention stent device of the present embodiment will be described with reference to the right femoral artery access as an example.

The method comprises the following steps:

1. disinfecting, paving and local anaesthesia the right inguinal region, puncturing the right femoral artery, placing a sheath tube, establishing a channel, delivering an angiographic guide wire and a catheter to a diseased blood vessel, pushing a contrast medium through the angiographic catheter, determining the shape of the blood vessel and the diseased region, pulling out the angiographic catheter and the guide wire, delivering the angiographic catheter and the guide wire, mounting the I-shaped inner leakage-proof stent 10 on a stent conveyor, conveying the conveyor to the diseased region of the blood vessel through the guide wire, gradually and uniformly releasing the stent with self-expansion characteristic by a releasing device, further sealing the blood flow in a tumor cavity by the I-shaped inner leakage-proof stent 10, and then withdrawing the conveying device and the guide wire to cover the diseased region.

2. The magnetic driver is moved to the position of the I-shaped innerleakage prevention support 10 in a human body, the distance between the twodrive plates 22 is adjusted, the I-shaped innerleakage prevention support 10 is located between the twodrive plates 22, thedrive plates 22 are electrified, thedrive plates 22 generate an external magnetic field, the I-shaped innerleakage prevention support 10 is heated and expanded in the magnetic field, theelastic grid layer 13 is expanded to fill the gap between the blood vessel wall and thefilm coating layer 12, thedrive plates 22 are closed, the magnetic driver is removed, the I-shaped innerleakage prevention support 10 is permanently placed at a pathological change position, and the purpose of sealing a tumor cavity is achieved.

During the operation, DSA (digital silhouette angiography) is used to monitor the whole process of the transporter entering the aorta from the arteriole in the human body and finally reaching the tumor cavity.

The second method comprises the following steps:

1. disinfecting, spreading towel and local anesthesia on right groin area, puncturing right femoral artery, inserting sheath tube, creating channel, delivering the contrast guide wire and catheter to the diseased blood vessel, pushing contrast medium in the contrast medium, determining the shape of blood vessel and diseased region, and delivering the contrast guide wire and guide wire. The I-shaped innerleakage prevention support 10 is arranged on a balloon catheter, is conveyed to a vascular lesion part through a guide wire and the balloon catheter, is injected with liquid by a pressure pump to expand the balloon, further struts the I-shaped innerleakage prevention support 10 to seal blood vessels on two sides of a tumor cavity, and then is withdrawn from the balloon catheter and the guide wire to enable the support to cover the lesion part.

2. The magnetic driver is moved to the position of the I-shaped innerleakage prevention support 10 in a human body, the distance between the twodrive plates 22 is adjusted, the I-shaped innerleakage prevention support 10 is located between the twodrive plates 22, thedrive plates 22 are electrified, thedrive plates 22 generate an external magnetic field, the I-shaped innerleakage prevention support 10 is heated and expanded in the magnetic field, theelastic grid layer 13 is expanded to fill the gap between the blood vessel wall and thefilm coating layer 12, thedrive plates 22 are closed, the magnetic driver is removed, the I-shaped innerleakage prevention support 10 is permanently placed at a pathological change position, and the purpose of sealing a tumor cavity is achieved.

In the operation process, the whole process that the catheter enters the aorta from the arteriole in the human body and finally reaches the tumor cavity is monitored by X-ray radiography video.

When a new arteriosclerosis plaque is newly generated on the vascular wall and a new gap is generated by jacking thefilm coating layer 12, the magnetic driver is used again, the I-shaped innerleakage prevention support 10 is positioned between the two drivingplates 22, the drivingplates 22 are electrified, the drivingplates 22 generate an external magnetic field, so that the I-shaped innerleakage prevention support 10 generates heat and expands in the magnetic field, theelastic grid layer 13 expands to fill the gap formed between the metal net-shapedsupport layer 11 supported by the arteriosclerosis plaque and the gap formed between thefilm coating layer 12 and the inner wall of the blood vessel, blood flow cannot directly rush into a tumor cavity, and blood in theelastic grid layer 13 can be solidified after a period of time, so that the tumor cavity is completely sealed, and the tumor cavity is in a stable state.

Effects and Effect of example 1

According to the support device that leaks in preventing I type that this embodiment provided, the blood vessel has been supported to the metal supporting layer, elasticity net layer covers on laminating layer, generate heat under the magnetic field that the magnetic particle magnetic drive ware that distributes in elasticity net layer produced, elasticity net layer expands under the heat effect, fill up the gap between laminating layer and the blood vessel inner wall, and because blood enters into elasticity net layer, the velocity of flow reduces, when the blood vessel has the hard piece of artery, the hard piece of artery is held in the recess, consequently elasticity net layer makes the leak department no longer bleed with laminating layer together, overcome the laminating layer and not have the recess, can't hold the hard piece of artery, thereby leave the defect that the gap made the leak department can't heal. Elastic grid layer fills up the space for blood flow can not directly rush into the tumor chamber, and blood can not be recharged in the tumor chamber, and the tumor chamber can get into stable state after the blood that persists in the tumor chamber solidifies, and then endothelial cell hyperplasia grows into the tumor chamber, makes the difficult emergence of tumor chamber break. When a new arteriosclerosis plaque is newly generated on the vessel wall and the tectorial membrane layer is jacked up to generate a new gap, the stent can be conveniently placed in the magnetic field again to expand the elastic grid layer, and then the gap is propped up by the arteriosclerosis plaque to be filled, so that the tumor cavity is completely sealed, and the tumor cavity is in a stable state. Therefore, a new stent does not need to be implanted again, so that the pain and the operation risk of a patient are reduced, and the medical resources are saved.

The magnetic field intensity of the magnetic driver is within the safety range of the human body, and the human body cannot be burnt.

The elastic mesh layer has two functions, namely physical barrier, so that the flow speed of blood at the position is greatly reduced, and coagulation is promoted; meanwhile, the grid structure also serves as a matrix formed by fibrosis, and is beneficial to the growth of fibroblasts, so that the tumor cavity is further stabilized.

After the tumor cavity is naturally sealed, the sealing material loses its effect, and the poly-L-lactic acid as a biological material is finally degraded into water and CO which are non-irritant and non-toxic to human bodies in vivo₂The magnetic particles are discharged out of the body along with metabolism, and do not stimulate the body.

The elastic grid layer is filled in a gap formed between the inner wall and the laminating layer under the action of elasticity of the elastic grid layer, when an arteriosclerosis plaque is arranged on a blood vessel wall, the elastic grid layer can fill the gap formed between the metal mesh supporting layer supported by the arteriosclerosis plaque and the laminating layer and the inner wall of the blood vessel, so that blood flow cannot directly rush into a tumor cavity, blood in the elastic grid layer can be solidified after a period of time, the tumor cavity is completely sealed, and the tumor cavity is enabled to enter a stable state.

The triangular meshes can save used materials, and the triangular structure has stability, so that the materials are not easy to extrude and deform due to expansion. On the other hand, the triangular grooves have certain spaces which can just accommodate the lower arteriosclerosis block after implantation, and meanwhile, the surface of the material is not completely covered by the flat temperature-control elastic material, and the arteriosclerosis block only needs to jack up the protruding edge between the arteriosclerosis block and the triangular grooves, so that the force for jacking up the material by the arteriosclerosis block is small, and conversely, the pressure of the stent on the arteriosclerosis block and the vessel wall is small, and the stimulation on the vessel is small.

In addition, the basic constitutional units of the elastic grid layer are in the shape of double triangular pyramids, and the long axis direction of the double triangular pyramids is perpendicular to the long axis direction of the stent, so that the double triangular pyramids are easier to deform after receiving a force which is applied by the blood vessel wall and is perpendicular to the long axis direction of the stent, and the I-shaped inner leakage between the elastic grid layer closed stent and the artery wall is more strictly filled.

In addition, because the length of the elastic mesh layer does not exceed the edges of the upper end and the lower end of the metal mesh supporting layer and the film coating layer, the elastic mesh layer can be prevented from extending out of the edge of the inner leakage prevention support to cause blood flow coagulation at the position to form thrombus, and the blood flow enters the blood vessel to embolize the blood vessel under the impact of the blood flow.

The device is simple to operate, and the diseased region in the DSA image can be released, so that the operation time can not be prolonged, and unnecessary risks are not brought. In addition, the magnetic driver has low manufacturing cost and can save medical resources.

< example 2>

In this embodiment, the same components as those in embodiment 1 are given the same reference numerals, and the same descriptions are omitted.

The inner leakage prevention bracket device of the present embodiment includes an innerleakage prevention bracket 30 and a magnetic driver. The structure is the same as that of example 1 except that the arrangement of theelastic mesh layer 13 and the magnetic particles are different from that of example 1.

Fig. 9 is a schematic view of the entire structure of the innerleakage prevention bracket 30 according to embodiment 2 of the present invention.

As shown in fig. 9, theelastic mesh layer 13 covers the proximal end and the distal end of thecoating layer 12, respectively, and the length of the elastic mesh layer does not exceed the edges of the upper and lower ends of the metal mesh support layer and the coating layer.

The magnetic particles are ferroferric oxide, the ferroferric oxide and the poly L-lactic acid are mixed according to the volume ratio of 45:60, and the ferroferric oxide is uniformly distributed in theelastic grid layer 13 through injection molding and laser engraving molding. The heat generated by the ferroferric oxide can heat theelastic mesh layer 13 to 45 ℃.

Effects and Effect of example 2

In addition to the effects and effects of embodiment 1, this embodiment also has the effects and effects of:

the advantage of having theresilient grid layer 13 both near and far ends is that it further prevents I-shaped internal leakage at the far end, which, although less likely, further enhances the safety of the stent.

In addition, the ferroferric oxide in the present embodiment has the same technical effects as the manganese-zinc-ferrite in embodiment 1, and the elastic mesh layer in the sample embodiment has the same actions and effects as the elastic mesh layer in embodiment 1.

The above embodiments are preferred examples of the present invention, and are not intended to limit the scope of the present invention.

In other embodiments, the elastic mesh layer may be formed by combining a plurality of polyhedral edges in other shapes. Such as hexahedrons or tetrahedrons. It is preferable to use one of the double triangular pyramids, i.e., the nonahedrons, employed in the embodiments of the present invention.

The major axis direction of the double triangular pyramids that adopts in the above embodiment is perpendicular to the major axis direction of whole support the utility model discloses preferred embodiment, in practical application, the major axis direction of double triangular pyramids and the major axis direction of whole support also can set up to other angles, as long as it is not parallel can, the angle between the two is close more the perpendicular angle effect better.

In other embodiments, the utility model discloses a laminating layer also can cover in the inboard of metal mesh supporting layer to elasticity net layer and metal mesh supporting layer lug connection, this kind of range upon range of order also can reach the technical effect of the utility model.

Claims (10)

1. The utility model provides a prevent leaking support device in I type for seal I type is interior to leak, its characterized in that includes:

an inner leakage prevention bracket and a magnetic driver,

wherein, leak in preventing support includes:

the metal mesh supporting layer is matched with the shape of an arterial blood vessel of a human body;

the film coating layer is covered on the metal reticular supporting layer;

the elastic grid layer is distributed at the proximal end outside the film coating layer or at the proximal end and the distal end outside the film coating layer; and

magnetic particles embedded in the elastic mesh layer,

the magnetic driver is used for being arranged at the position of the inner leakage prevention support to generate a magnetic field, and the magnetic particles convert magnetic field energy of the magnetic field into heat energy, so that the elastic grid layer deforms along with the change of temperature and is filled in a gap formed by the inner wall of the artery blood vessel and the tectorial membrane layer.

2. The type I endoleak prevention stent device according to claim 1, wherein:

wherein the elastic mesh layer does not extend beyond the edges of the ends of the metallic mesh support layer and the overlaminate layer.

3. The type I endoleak prevention stent device according to claim 1, wherein:

wherein, the thickness of the elastic grid layer is 1 mm-5 mm.

4. The type I endoleak prevention stent device according to claim 1, wherein:

the elastic grid layer is provided with grooves which are triangular grooves, the elastic grid layer is formed by combining edges of a plurality of polyhedrons into triangular grids which are uniformly arranged, and the triangular grids are provided with the triangular grooves.

5. The type I endoleak prevention stent device according to claim 4, wherein:

the polyhedron is a double-triangular pyramid, and the long axis direction of the double-triangular pyramid is perpendicular to the long axis direction of the internal leakage prevention support.

6. The type I endoleak prevention stent device according to claim 5, wherein:

the double triangular cone columns are connected side by side to form a single layer, the single layer is staggered at the joint of the two double triangular cone columns to form a multilayer staggered structure, and the multilayer structure forms a cylinder shape and surrounds the outer side of the coating layer.

7. The type I endoleak prevention stent device according to claim 1, wherein:

wherein the volume ratio of the magnetic particles to the elastic grid layer is 45: 100-75: 100,

the elastic grid layer is made of poly L-lactic acid.

8. The type I endoleak prevention stent device according to claim 1, wherein:

wherein the magnetic particles are manganese zinc ferrite or ferroferric oxide.

9. The type I endoleak prevention stent device according to claim 1, wherein:

wherein the intensity of the magnetic field generated by the magnetic driver is 1kA/m to 50 kA/m.

10. The type I endoleak prevention stent device according to claim 1, wherein:

the magnetic driver comprises a vertically arranged driving arm and two driving plates which are arranged on the driving arm in an up-and-down parallel mode, a plurality of excitation groups are arranged in the driving plates, and the excitation groups generate magnetic fields when electrified.

Images